Home > Insider Trading > Filing (0000929638-23-000867)

Filing Details

Accession Number:: 0000929638-23-000867
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-03-16 18:04:35
Reporting Period:: 2023-03-14

Accepted Time:: 2023-03-16 18:04:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1836056	Ambrx Biopharma Inc.	AMAM	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1583977	Cormorant Asset Management, Lp	200 Clarendon Street 52Nd Floor Boston MA 02116	No	No	No	No
1599214	Bihua Chen	C/O Cormorant Asset Management, Lp 200 Clarendon Street, 52Nd Floor Boston MA 02116	No	No	No	No
1618442	Cormorant Global Healthcare Master Fund, Lp	200 Clarendon Street 52Nd Floor Boston MA 02116	No	No	No	No
1817320	Cormorant Private Healthcare Fund Iii Lp	200 Clarendon Street 52Nd Floor Boston MA 02116	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2023-03-14	250,000	$9.95	52,750,000	No	4	P	Indirect	See Footnotes
Ordinary Shares	Acquisiton	2023-03-15	250,000	$10.60	53,000,000	No	4	P	Indirect	See Footnotes
Ordinary Shares	Acquisiton	2023-03-16	500,000	$10.15	53,500,000	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Footnotes

Represents the weighted average sale price of American Depository Shares ("ADS") purchased in a series of open market transactions on the transaction date at prices ranging from $9.12 to $10.66 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by the Master Fund (as defined below).
Information reported herein relates to ordinary shares represented by ADS owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund III, LP ("Fund III"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund III. Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP III, LLC ("GP III") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Represents (i) 43,021,365 ordinary shares beneficially owned by the Master Fund and (ii) 9,728,635 ordinary shares beneficially owned by Fund III.
Represents the weighted average sale price of ADS purchased in a series of open market transactions on the transaction date at prices ranging from $10.295 to $11.045 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by the Master Fund.
Represents (i) 43,271,365 ordinary shares beneficially owned by the Master Fund and (ii) 9,728,635 ordinary shares beneficially owned by Fund III.
Represents the weighted average sale price of ADS purchased in a series of open market transactions on the transaction date at prices ranging from $9.65 to $10.35 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by the Master Fund.
Represents (i) 43,771,365 ordinary shares beneficially owned by the Master Fund and (ii) 9,728,635 ordinary shares beneficially owned by Fund III.